AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20440520
Drug: Cyclo +
RxNorm normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclo + mtx (cyclosporin at 7.5 mg/kg/day for 6 weeks, then 4 mg/kg/day + methotrexate at 5 mg/kg/week for 1 year)
Trial: 20440520
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard insulin therapy)
Trial: 16249142
Drug: Narrowband blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband blue light treatment (8 sessions of 10- or 20-minute treatments over 4 weeks)
Trial: 16249142
Drug: Narrowband blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrowband blue light treatment
Trial: 1959800
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III concentrate administration during surgery
Trial: 6115807
Drug: Ranitidine 100
RxNorm normalized name: ranitidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 100 mg, taken twice a day
Trial: 6115807
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken twice a day
Trial: 28950351
Drug: CPB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPB plus cixutumumab 6 mg/kg i.v. weekly
Trial: 15717138
Drug: Acute TD-GTN
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute TD-GTN 20 mg
Trial: 26055927
Drug: Oral vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vancomycin 125mg every 6 hours for 10 days
Trial: 19239555
Drug: 0.75% adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% adenosine lotion
Trial: 14585873
Drug: Individual dose
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual dose of rFSH (100-250 IU/day)
Trial: 14585873
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of rFSH (150 IU/day)
Trial: 2857910
Drug: Povidone-iodine 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine 2% (50 ml instilled before catheter removal)
Trial: 30805708
Drug: Cement augmentation
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cement augmentation of PHILOS screws (augmented group)
Trial: 30805708
Drug: PHILOS screws
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PHILOS screws without cement augmentation (control group)
Trial: 16087956
Drug: Sequential chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiotherapy (induction CT with cisplatin 120 mg/m2 on days 1, 29, and 57; vinorelbine 30 mg/m2/wk from day 1 to day 78; followed by thoracic RT at 66 Gy in 33 fractions)
Trial: 16087956
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (RT started on day 1 with two cycles of cisplatin 20 mg/m2/d and etoposide 50 mg/m2/d; consolidation therapy with cisplatin 80 mg/m2 on days 78 and 106; vinorelbine 30 mg/m2/wk from days 78 to 127)
Trial: 19910828
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (no treatment applied)
Trial: 15329509
Drug: Pravastatin (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10-20 mg) plus diet
Trial: 9283055
Drug: Estradiol valeranate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valeranate 10 mg (E)
Trial: 9283055
Drug: Estradiol valeranate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valeranate 4 mg plus prasterone enantate 200 mg (E+P)
Trial: 8510192
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (nicotine gum)
Trial: 3305207
Drug: Monthly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly maintenance chemotherapy for 2 years (Group A)
Trial: 3305207
Drug: Monthly maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly maintenance chemotherapy plus viral oncolysate injection on day 15 (Group A+IT)
Trial: 3305207
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy after early consolidation
Trial: 23650800
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) intervention applied to bilateral Xuehai (SP 10), Zusanli (ST36), Taichong (LR3), and Sanyinjiao (SP 6) for 30 min, once daily for 15 days.
Trial: 23650800
Drug: Intensive endurance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive endurance exercise (Harvard step test) for 30 min, once daily for 15 days.
Trial: 21091250
Drug: Lactotripeptides (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactotripeptides (3 mg of Ile‐Pro‐Pro/Val‐Pro‐Pro)
Trial: 18209670
Drug: OTZ (oxothiazolidine‐4‐carboxylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTZ (oxothiazolidine‐4‐carboxylic acid) 210 mg/kg per day every 8 hrs for 14 days
Trial: 16599263
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (4 x 5 g daily for 6 weeks)
Trial: 15128893
Drug: Concurrent cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin (100 mg/m² IV on days 1, 22, and 43) plus radiotherapy (60 to 66 Gy in 30 to 33 fractions over 6 to 6.6 weeks)
Trial: 15128893
Drug: Concurrent cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin plus radiotherapy
Trial: 8065733
Drug: Intraligamentary injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamentary injection of slow-release methylprednisolone (Depomedrol)
Trial: 3418088
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA) enemas (2 g in 100 ml)
Trial: 3418088
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA) suppositories (1 g b.i.d.)
Trial: 30902603
Drug: Cylindrical implants
RxNorm normalized name: Imperata cylindrica root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cylindrical implants
Trial: 28557376
Drug: Both tapered
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both tapered and cylindrical implants
Trial: 9438598
Drug: 40-Gy radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40-Gy radiotherapy and 4 weeks 5-FU treatment
Trial: 7512469
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR 240mg daily
Trial: 7512469
Drug: Enalapril 20mg
RxNorm normalized name: enalapril 20 MG
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril 20mg daily
Trial: 7512469
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Verapamil + Enalapril or Hydrochlorothiazide)
Trial: 3520382
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO) - 20 consecutive daily treatments of 100% O2 followed by 7 booster treatments over 6 months
Trial: 29568976
Drug: Intranasal naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal naloxone 0.8 mg
Trial: 29568976
Drug: Intramuscular naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular naloxone 0.8 mg
Trial: 21756847
Drug: PegIFNα2a 180
RxNorm normalized name: peginterferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PegIFNα2a 180 μg/wk plus daily Rbv 800-1200 mg
Trial: 21756847
Drug: PegIFNα2b 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNα2b 1.5 μg/kg/week plus daily Rbv 800-1200 mg
Trial: 20735515
Drug: SRP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP plus 500 mg of azithromycin per day (3 days)
Trial: 12830040
Drug: Intermittent hyperkalemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent hyperkalemic cold blood cardioplegia and topical cardiac cooling (Control)
Trial: 10806608
Drug: tolbutamide 500
RxNorm normalized name: tolbutamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolbutamide 500 mg plus tolcapone 200 mg
Trial: 10806608
Drug: tolbutamide 500
RxNorm normalized name: tolbutamide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolbutamide 500 mg plus placebo
Trial: 29504812
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec FlexTouch®
Trial: 26843473
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release hGH (SR-hGH) 2-mg injections weekly for 3 months
Trial: 21126667
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (10 mg)
Trial: 21126667
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine (10 mg) with morphine (100 mcg)
Trial: 21126667
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine (10 mg)
Trial: 21126667
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine (10 mg) with morphine (100 mcg)
Trial: 9202548
Drug: Patient-Controlled Analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Analgesia (PCA) with intravenous alfentanil, mean dose 1.03 mg
Trial: 9202548
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with intravenous pethidine, mean dose 62.5 mg
Trial: 1527232
Drug: Carbamazepine and
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine and valproic acid combination
Trial: 30457892
Drug: Turmeric-containing herbal
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric-containing herbal combination tablets
Trial: 30470580
Drug: Delayed-release dimethyl
RxNorm normalized name: dimethyl fumarate Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release dimethyl fumarate (DMF) 240 mg BID
Trial: 24989666
Drug: Delayed-release dimethyl
RxNorm normalized name: dimethyl fumarate Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release dimethyl fumarate (DMF) 240 mg TID
Trial: 20826249
Drug: Bone marrow-derived
RxNorm normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived mononuclear cells (BMCs) - 100 million intracoronary BMCs administered 3 to 10 days post-procedure
Trial: 15781538
Drug: hyperbaric intrathecal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hyperbaric intrathecal solution of 10 mg bupivacaine
Trial: 15781538
Drug: isobaric intrathecal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isobaric intrathecal solution of 10 mg bupivacaine
Trial: 15781538
Drug: hypobaric intrathecal
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hypobaric intrathecal solution of 10 mg bupivacaine
Trial: 12552188
Drug: EDTA-containing propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA-containing propofol (ECP) 2 mg/kg
Trial: 12552188
Drug: Sulfite-containing propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfite-containing propofol (SCP) 2 mg/kg
Trial: 10826131
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of cyanamide
Trial: 10826131
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of cyanamide at 0.3 mg/kg
Trial: 10826131
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of cyanamide at 1.0 mg/kg
Trial: 10826131
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of cyanamide at 1.5 mg/kg
Trial: 6984828
Drug: BCG vaccine,
RxNorm normalized name: BCG vaccine, live INJECTION VIAL (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG vaccine, administered as a series of four weekly intradermal injections.
Trial: 31782747
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of care
Trial: 31782747
Drug: BMI and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMI and insulin levels correlation
Trial: 27486985
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of Cb with SIT
Trial: 25280441
Drug: GNB3 C825T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNB3 C825T polymorphism homozygous CC group
Trial: 14566442
Drug: Deramciclane (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deramciclane (60 mg for 8 days)
Trial: 10991864
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg of VGC per os (p.o.) once a day (q.d.)
Trial: 10991864
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of VGC p.o. q.d.
Trial: 10991864
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of oral GCV three times a day
Trial: 10991864
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of intravenous (i.v.) GCV per kg of body weight q.d.
Trial: 9236310
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral ritodrine from the 25th to the end of the 37th week of gestation
Trial: 1358620
Drug: Ethanol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.8 g.kg‐1)
Trial: 30817250
Drug: FOLFIRINOX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX plus Pegylated Recombinant Human Hyaluronidase (PEGPH20) at a dosage of 3 µg/kg every 2 weeks
Trial: 21774293
Drug: Telephone-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based intervention (TBI) with motivational interviewing and supportive techniques, individual weekly therapy sessions of 20 to 30 minutes via telephone for six weeks.
Trial: 19547854
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy in the postoperative recovery room and subsequently in the infirmary
Trial: 19547854
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy in the infirmary exclusively
Trial: 16752186
Drug: Adiponectin concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adiponectin concentrations in the third trimester (9.9+/‐1.4 microg/ml) compared to pregravid condition (13.5+/‐1.8 microg/ml)
Trial: 16752186
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion in pregravid women
Trial: 16752186
Drug: Relationship between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relationship between adiponectin and insulin sensitivity
Trial: 11291551
Drug: Famciclovir 500
RxNorm normalized name: famciclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 500 mg three times daily for 10 days
Trial: 11291551
Drug: Acyclovir 800
RxNorm normalized name: acyclovir 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 800 mg five times daily for 10 days
Trial: 9725757
Drug: lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam (2 mg) and oxazepam (30 mg)
Trial: 7986772
Drug: Combined amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined amphetamine (0.3 mg/kg) with haloperidol (2 mg)
Trial: 7986772
Drug: Amphetamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (0.3 mg/kg)
Trial: 5296380
Drug: Home treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home treatment with isoniazid plus PAS
Trial: 5296380
Drug: Sanatorium treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanatorium treatment with isoniazid plus PAS
Trial: 23064079
Drug: Bupropion (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (75 mg twice a day for 7 days)
Trial: 21535995
Drug: Olanzapine 5-10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5-10 mg/d
Trial: 21535995
Drug: Olanzapine 2.5
RxNorm normalized name: olanzapine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 2.5 mg/d
Trial: 8290661
Drug: Venlafaxine 150-200
RxNorm normalized name: venlafaxine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 150-200 mg/day
Trial: 8290661
Drug: Venlafaxine 50-75
RxNorm normalized name: venlafaxine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 50-75 mg/day
Trial: 8290661
Drug: Venlafaxine 25
RxNorm normalized name: venlafaxine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 25 mg/day
Trial: 28166751
Drug: Generic pamphlet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic pamphlet on colorectal cancer treatment (Control group).
Trial: 16245914
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection
Trial: 16245914
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (western medicine only)
Trial: 12044376
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous fluids in accordance with hospital practice (> or = 3 L water and 154 mmol sodium per day)
Trial: 12044376
Drug: Restricted intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted intake (< or = 2 L water and 77 mmol sodium per day)
Trial: 12044376
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous fluids in accordance with hospital practice
Trial: 2665554
Drug: 1.7 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 g/kg alcohol drink on Days 1-4, placebo on Day 5
Trial: 627302
Drug: Floctafenine (Idarac)
RxNorm normalized name: floctafenine
DrugBank: Floctafenine (DB08976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floctafenine (Idarac) 200 mg four times daily
Trial: 627302
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg four times daily
Trial: 28454795
Drug: Serial human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serial human antimurine antibody assessments
Trial: 25841317
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (non-CXL)
Trial: 19571762
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block (18 ml of 0.25% bupivacaine)
Trial: 19571762
Drug: Combined superficial
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined superficial and deep cervical plexus block (14 ml superficial + 4 ml deep of 0.25% bupivacaine)
Trial: 17268410
Drug: 5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/day inulin
Trial: 17268410
Drug: 8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/day inulin
Trial: 17268410
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 8 g/day)
Trial: 12716777
Drug: murabutide 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: murabutide 7 mg/day on five consecutive days/week
Trial: 12716777
Drug: murabutide 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: murabutide 7 mg/day
Trial: 7483792
Drug: TBE vaccine
RxNorm normalized name: TBE vaccine
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBE vaccine on days 0 and 28